Uveal melanoma

12 trials 10 recruiting MedDRA PT
12 Registered trials
10 Recruiting
9 Unique sponsors
11 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 3
N Neurology/Psychiatry (ATC N) 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Checkpoint inhibitor (PD-1) 2 substances
Alkylating agent 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase III: 6 Phase II/III: 3 Phase II: 3 Phase I (First in Human): 1

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

6 trials
  • Aura Biosciences Inc. Commercial
    BELZUPACAP SAROTALOCAN
    2023-504655-27-00 12 countries 2024 n=142 Orphan
    Recruiting
  • Ideaya Biosciences Inc. Commercial
    DAROVASERTIB
    2025-522387-32-00 10 countries 2026 n=297 Orphan
    Recruiting
  • European Organisation For Research And Treatment Of Cancer Academic
    TEBENTAFUSP
    2023-510333-28-00 9 countries 2025 n=200 Orphan
    Recruiting
  • St Erik Eye Hospital Academic
    MELATONIN
    2022-500307-49-00 1 country 2022 n=100
    Recruiting
  • Vaestra Goetalandsregionen Academic
    IPILIMUMAB; NIVOLUMAB
    2023-508156-20-00 2 countries 2024 n=50
    Recruiting
  • St Erik Eye Hospital Academic
    MELATONIN
    2022-500307-49-00 1 country 2022 n=100
    Recruiting

Phase II/III

3 trials
  • Ideaya Biosciences Inc. Commercial
    DAROVASERTIB
    2023-506686-66-00 1 country n=10
    Not authorised
  • Ideaya Biosciences Inc. Commercial
    DAROVASERTIB
    2023-506686-66-01 7 countries 2024 n=154
    Recruiting
  • Immunocore Limited Commercial
    PEMBROLIZUMAB; TEBENTAFUSP
    2022-502732-39-00 7 countries 2023 n=363 Orphan
    Recruiting

Phase II

3 trials
  • Ideaya Biosciences Inc. Commercial
    DAROVASERTIB
    2023-506683-14-00 4 countries 2024 n=36
    Ended
  • iOnctura SA Commercial
    DACARBAZINE CITRATE; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB; ROGINOLISIB
    2024-514333-37-00 2 countries 2025 n=43
    Recruiting
  • Grupo Espanol Multidisciplinar De Melanoma Academic
    TEBENTAFUSP
    2023-509076-42-00 2 countries 2025 n=19 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    DYP688
    2023-509451-14-00 4 countries 2022 n=27
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ideaya Biosciences Inc. Commercial 4 Phase II/III, Phase II, Phase III 2
St Erik Eye Hospital Academic 2 Phase III 2
Immunocore Limited Commercial 1 Phase II/III 1
iOnctura SA Commercial 1 Phase II 1
Aura Biosciences Inc. Commercial 1 Phase III 1
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
Grupo Espanol Multidisciplinar De Melanoma Academic 1 Phase II 1
European Organisation For Research And Treatment Of Cancer Academic 1 Phase III 1
Vaestra Goetalandsregionen Academic 1 Phase III 1
New trials by year
2022
3
2023
1
2024
4
2025
3
2026
1
← All indication landscapes